Definium Therapeutics

Definium Therapeutics

Yahoo Finance • 2 days ago

Definium Therapeutics (DFTX) Redefines Depression & Anxiety Treatment

Meridian Funds, managed by ArrowMark Partners, released its second-quarter 2026 investor letter for "Meridian Small Cap Growth Fund". A copy of the letter can be downloaded here. The U.S. market saw a strong rally in the second quarter, fu... Full story

Yahoo Finance • 9 days ago

Psychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Rosén & President Alison Silva

Watch Fireside Chat Below, or Click HERE: IPO Edge hosted a fireside chat with Jupiter Neurosciences, Inc. (Nasdaq: JUNS) Chairman, Chief Executive Officer and Co-founder Christer Rosén and Alison Silva, President and Chief Operations Off... Full story

Yahoo Finance • 16 days ago

Which Pharmaceuticals ETF Is Better, the iShares IHE or State Street XPH?

The iShares U.S. Pharmaceuticals ETF (NYSEMKT:IHE) offers heavy exposure to pharmaceutical giants and a higher yield, while the State Street SPDR S&P Pharmaceuticals ETF (NYSEMKT:XPH) provides broader, more equal-weighted exposure. Both f... Full story

Yahoo Finance • 17 days ago

The Race to Commercialize the World’s Most Powerful Psychedelic

An obscure psychedelic is drawing intense interest from the pharmaceutical industry. WSJ explores why companies are betting hundreds of millions of dollars on the therapeutic potential of a toad poison. View Comments... Full story

Yahoo Finance • 22 days ago

Leaderboard Quarterly Scorecard Webinar Q&A Summary For Thursday, July 9, 2026

Thank you very much for attending! Question Answer Lots of reverb! Close zoom down and re-open the webinar Interesting issue of whether bio/medical, software, financials, small caps are just a rotation play versus an enduring trend, and wh... Full story

Yahoo Finance • last month

Is Definium Therapeutics, Inc. (DFTX) Stock Poised for Further Gains After Positive Emerge Trial Update?

We recently compiled a list of the 10 Best Biotech Stocks to Buy According to Analysts. Definium Therapeutics, Inc. (NASDAQ:DFTX) is one of the best biotech stocks on this list. TheFly reported on June 23 that Robert W. Baird analyst Chri... Full story

Yahoo Finance • last month

Stocks Mostly Lower on Weakness in Megacap Tech and Software Stocks

The S&P 500 Index ($SPX) (SPY) on Monday closed down -0.37%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.29%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.19%.  September E-mini S&P futures (ESU26) fell -0.34%, and... Full story

Yahoo Finance • last month

Stocks Erase Early Gains as Alphabet and Software Companies Fall

The S&P 500 Index ($SPX) (SPY) today is down -0.40%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.27%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.30%.  September E-mini S&P futures (ESU26) are down -0.38%, and September E... Full story

Yahoo Finance • last month

Stocks Supported by Strength in Chipmakers and AI-Infrastructure Stocks

The S&P 500 Index ($SPX) (SPY) today is up +0.21%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.54%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.50%.  September E-mini S&P futures (ESU26) are up +0.20%, and September E-mini... Full story

Yahoo Finance • last month

Pre-Market Movers: TNON, ADTX, LNAI See Sharp Moves

(RTTNews) - Biotech companies are seeing significant pre-market activity this Monday. Pre-market movers give traders an early read on momentum, sentiment, and potential volatility for the trading day. Price swings before the opening bell... Full story

Yahoo Finance • 2 months ago

Generalized Anxiety Disorder Market Forecast Shows Strong CAGR During the Forecast Period (2026-2036) Driven by Innovative Therapies | DelveInsight

The generalized anxiety disorder market across the 7MM is expected to grow significantly during the forecast period (2026-2036). Key drivers include the increasing prevalence of the disease, advancements in diagnostic tools, heightened pat... Full story

Yahoo Finance • 2 months ago

Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish

Octagon Capital Advisors cut its stake in Dianthus Therapeutics(NASDAQ:DNTH) by 470,000 shares, an estimated $27.22 million trade based on quarterly average pricing, according to a May 15, 2026 SEC filing. What happened According to a SE... Full story

Yahoo Finance • 3 months ago

Trump Just Fast-Tracked Psychedelic Treatments: 3 Under-the-Radar Stocks That Could Be About to Soar

Over the weekend, President Donald Trump fast-tracked the approval process for psychedelic treatments for mental illnesses. Trump signed an order that directs the Food and Drug Administration (FDA) to ease restrictions on and speed up rev... Full story

Yahoo Finance • 3 months ago

Trump issues executive order on psychedelic drugs

[President Trump Signs Executive Order At The White House] Tasos Katopodis/Getty Images News President Donald Trump on Saturday signed an executive order to expedite access to research and treatments ​based on psychedelic drugs, a move th... Full story

Yahoo Finance • 4 months ago

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Key Takeaways; Cannabis Sector Tilray Brands Global Push is Paying Off as International Cannabis Growth Drove Record Q3 Revenue Charlotte’s Web Strengthened Balance Sheet as British American Tobacco Deepened Stake Amid Strategic Growth Pu... Full story

Yahoo Finance • 4 months ago

This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names

On February 17, 2026, Superstring Capital Management disclosed a new position in Definium Therapeutics(NASDAQ:DFTX), acquiring 425,202 shares in the fourth quarter. What happened According to a SEC filing dated February 17, 2026, Superst... Full story